VERACODE
Centrico Spa, part of Sella Group and a specialist in providing open banking systems for innovation-oriented financial institutions, has entered a collaboration with Veracode, a global leader in application security risk management. The deal will enhance the analysis, detection, and prioritization of flaws to expedite software fixes at every stage of Centrico’s application development life cycle.
Modern banking and finance are exposed to a stringent and evolving landscape, not least as a result of the Digital Operational Resilience Act (DORA) and an increase in frequent and sophisticated cyberattacks. As revealed in Veracode’s State of Software Security Report 2023, during code-checking activities Veracode identified and reported potential vulnerabilities in 72 percent of its financial sector clients' applications—the lowest percentage of all sectors analyzed and an improvement from the previous year.
Centrico's goal is to minimize risk at the application development level and avoid dangerous flaws that could significantly impact the entire supply chain. After a careful selection process, Veracode was chosen to strengthen the security of Centrico’s application development through the integration of testing and analysis tools that detect and eliminate vulnerabilities.
Veracode’s high level of reliability and accuracy in flaw analysis, its effective and rapid resolution capabilities, and its innovative vision highlighted the company’s ability to respond in the best possible way to the demands of the numerous companies operating in this sector. Centrico is composed of an international team of experts with deep knowledge of the financial industry, specializing in open-core banking and business process outsourcing services. Its solutions are based on cutting-edge technologies that are innovative for the industry. The core banking platform and solutions are customer-oriented, reduce time to market, are open to the integration of external services, and inspired by principles of eco-sustainability.
Veracode's software security platform continually detects flaws and vulnerabilities at every stage of the modern software development life cycle. Thanks to a powerful artificial intelligence engine trained on trillions of lines of code, it automatically generates suggested fixes for vulnerabilities found during scanning, thus preventing insecure code from spreading to other applications.
"For Veracode in Italy, this agreement is a testimony of great importance and a reason for satisfaction. We are very proud to support Centrico in the development of secure applications and to collaborate in the detection and resolution of any potential flaws," said Massimo Tripodi, Country Manager of Veracode Italy. "The financial services sector is a constant target of cyberattacks that exploit different vectors and channels, so it is essential that companies can operate with inherently secure applications, reducing risk within code."
About Veracode
Veracode is intelligent software security. The Veracode Software Security Platform continuously finds flaws and vulnerabilities at every stage of the modern software development life cycle. Using powerful AI trained on a carefully curated, trusted dataset from experience analyzing trillions of lines of code, Veracode customers fix flaws faster with high accuracy. Trusted by security teams, developers, and business leaders from thousands of the world’s leading organizations, Veracode is the pioneer, continuing to redefine what intelligent software security means.
Learn more at www.veracode.com, on the Veracode blog, and on LinkedIn and Twitter
About Centrico
Centrico, created in June 2018, is currently 83.98% owned by Banca Sella and 16.02% owned by Banca Sella Holding. In 2023, Centrico's total revenues amounted to 104.5 million euros (+21.3% compared to 2022). It provides unique core and digital banking solutions and a wide range of Information Technology and Business Process Outsourcing services to both Sella Group companies and banks, FinTechs and other innovative financial operators. It aims to contribute to the development of the Italian financial ecosystem by bringing the Group's expertise and technology, open and unique solutions in the sector, to the market.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240318841982/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Seoul Semiconductor: Philips Lighting Products Ordered to Recall 7-Year-Old Items26.12.2024 08:00:00 CET | Press release
The German District Court of Düsseldorf, on November 19 ruled in favor of Seoul Semiconductor (KOSDAQ:046890) in the patent infringement lawsuits, and also ordered that products manufactured by Philips Lighting and sold since March 2017 be recalled and destroyed. The Court also ruled that a fine of up to €250,000 would be imposed for each violation of this order. On December 17, the German Federal Patent Court also affirmed the validity of these patents, which solidifies the strength of many related patents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225151382/en/ Application Examples with CRI 70 or Higher (Photo: Seoul Semiconductor) These court orders relate to the core technology used to achieve CRI 70 (Color Rendering Index 70%) or higher, applicable to all home lighting, automotive lighting products, IT flash, and backlights. Since the effects of these judgments are applicable to all products infringing on the pa
ispace-EUROPE and the Italian Space Agency (ASI) Sign Payload Services Agreement to Transport a Laser Retroreflector Array (LaRA2) on the Moon Surface26.12.2024 08:00:00 CET | Press release
Agreement Marks Significant Step Towards Increasing Italy’s Contribution to advancing Lunar Exploration ispace EUROPE S.A. (ispace-EUROPE), the Luxembourg-based subsidiary of ispace, inc., and the Italian Space Agency (ASI) have signed a payload services agreement to transport a Laser Retroreflector Array (LaRA2) to enable accurate position measurements on the Moon via laser ranging experiments, the two organizations announced today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225137548/en/ The shape of LaRA2, a palm-sized dome (Photo: Business Wire) The agreement marks the first full-scale contract between ispace-EUROPE and ASI, with both organizations looking to joint future lunar development. LaRA2 is a small, robust, and lightweight instrument built to work without any power source and to survive the harsh surface conditions on the Moon for an extended period of time. It features a precise array of retroreflectors
Datopotamab Deruxtecan Application in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Voluntarily Withdrawn24.12.2024 08:00:00 CET | Press release
Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have voluntarily withdrawn the marketing authorization application (MAA) in the EU for datopotamab deruxtecan (Dato-DXd) for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) based on the TROPION-Lung01 phase 3 trial. The decision to withdraw the MAA was informed by feedback from the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA). Daiichi Sankyo and AstraZeneca will continue to work to bring datopotamab deruxtecan to patients with lung cancer in the EU who can benefit and are committed to unlocking the potential of this medicine in lung cancer through our robust clinical development program which includes seven pivotal trials in various lung cancer settings. Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed by Dai
Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 1323.12.2024 22:05:00 CET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 10:30 a.m. ET/7:30 a.m. PT. A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com in the "Investors" section under the "News and Events" page. A replay of the conference webcast will be archived on the company's website. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia — and continues to advance clinical and research programs in these diseases. Vertex also has a robust clinical pipeline of investigational
Perma-Pipe International Holdings, Inc. Announces Third Quarter Financial Results23.12.2024 18:43:00 CET | Press release
The Company generated net sales of $41.6 million for the quarter and $113.4 million year-to-dateIncome before income taxes of $5.1 million for the quarter and $13.2 million year-to-dateBacklog of $114.2 million at October 31, 2024, compared to $68.5 million at January 31, 2024 Perma-Pipe International Holdings, Inc. (NASDAQ: PPIH) announced today financial results for the second quarter and fiscal year-to-date period ended October 31, 2024. "Net sales for the third quarter were $41.6 million, a decrease of $4.1 million, as compared to the same quarter last year. Net income attributable to common stock of $2.5 million was an increase of $0.5 million, or 29%, compared to $1.9 million in the third quarter of 2023. For the nine months ended October 31, 2024, net sales of $113.4 million represent an increase of 3% compared to the nine months ended October 31, 2023. The net income attributable to common stock of $7.2 million was an increase of $5.4 million, or 294%, compared to net income at
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom